On March 14, 2022, Mr. James C. D'Arecca, principal financial officer of TherapeuticsMD, Inc., notified the company of his decision to resign from such position, effective as of April 1, 2022. Mr. Michael C. Donegan, the Vice President Finance and Chief Accounting Officer of the company, will succeed Mr. D'Arecca as principal financial and accounting officer as of the effective date of Mr. D'Arecca's resignation.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.03 USD | 0.00% | +7.98% | -9.78% |
Mar. 29 | TherapeuticsMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Feb. 06 | Knight Therapeutics Announces Launch of Bijuva in Canada | MT |
1st Jan change | Capi. | |
---|---|---|
-9.78% | 23.41M | |
+7.91% | 72.81B | |
+12.64% | 9.13B | |
-10.56% | 5.13B | |
+58.79% | 4.99B | |
+4.07% | 3.9B | |
-16.90% | 2.48B | |
-26.13% | 2.32B | |
+19.31% | 2.17B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- TXMD Stock
- News TherapeuticsMD, Inc.
- TherapeuticsMD, Inc. Announces Executive Changes, Effective April 1, 2022